Aura Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
AURA$7.65-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months EndedJune 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(79,322) | $(54,502) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 534 | 577 |
| Accretion income on marketable securities | (632) | (785) |
| Stock-based compensation expense | 16,192 | 7,347 |
| Other non-cash items | 19 | 27 |
| Non-cash lease expense | 835 | 757 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 310 | 2,882 |
| Other long-term assets | (668) | 333 |
| Accounts payable | 698 | (1,018) |
| Accrued expenses and other liabilities | 423 | 910 |
| Operating lease liabilities | (783) | (657) |
| Net cash used in operating activities | (62,394) | (44,129) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (123) | (226) |
| Purchases of marketable securities | (256,014) | (9,984) |
| Maturities of marketable securities | 85,000 | 60,000 |
| Net cash provided by (used in) investing activities | (171,137) | 49,790 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 136 | 2 |
| Proceeds from exercise of common stock warrants | 123 | — |
| Proceeds from issuance of common stock from follow-on offering, net of issuance costs | 259,384 | 46,517 |
| Proceeds from issuance of pre-funded warrants from follow-on offering, net of issuance costs | 21,381 | 14,156 |
| Proceeds from issuance of common stock warrants from follow-on offering, net of issuance costs | — | 9,254 |
| Repurchase of common stock, including transaction costs | (39,093) | — |
| Proceeds from ESPP purchases | 121 | 96 |
| Net cash provided by financing activities | 242,052 | 70,025 |
| Net increase in cash, cash equivalents and restricted cash | 8,521 | 75,686 |
| Effect of exchange rate changes on cash and cash equivalents | (200) | (12) |
| Cash, cash equivalents and restricted cash at beginning of period | 60,283 | 32,461 |
| Cash, cash equivalents and restricted cash at end of period | $68,604 | $108,135 |
| Supplemental disclosure of cash flow information: | ||
| Purchases of property and equipment in accounts payable and accrued expenses and other liabilities | 7 | — |
| The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amounts shown in the unaudited condensed consolidated statements of cash flows (in thousands): | ||
| June 30, | ||
| 2026 | 2025 | |
| Cash and cash equivalents, end of period | $67,836 | $107,367 |
| Long-term restricted cash, end of period | 768 | 768 |
| Cash, cash equivalents and restricted cash at end of period | $68,604 | $108,135 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.